Page 2 - Donna Ryan News Today

When Jimmy Kimmel joked about Ozempic at the Oscars in 2023, the gag confirmed the drugs status as one of the most hyped treatments in American history. Heres how it happened.

Here is an expertly curated post-baby skincare routine for new mothers like Kourtney Kardashian who has given birth to baby Rocky with her Blink-182 drummer husband Travis Barker

Novo Nordisk, a Danish pharmaceutical company renowned for its diabetes medicines, is now positioning itself as the worlds leading weight-loss company. The company aims to target the global population of 764 million people with obesity, with the United States being its most lucrative market. In the U.S., where over two-thirds of adults are either overweight or obese, Novo charges customers $1,300 per month for the weekly injection of Wegovy.

Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the American obesity crisis: their prescription pads. Counseling on...

The Pharmaceutical giant behind obesity drug Wegovy has shelled out millions of dollars to incentivize doctors to prescribe the medicine, an analysis has found.

<p>New findings show that the medication known as Wegovy® (semaglutide) can reduce existing heart disease in patients with obesity by 20%, according to a study co-authored by past presidents of The Obesity Society and published in <em>The</em> <em>New England Journal of Medicine</em>.</p>

Who doesn't dream of traveling during their retirement years? While travel is considered an important retirement goal for many, retirees often need to err on the side of financial practicality. In a...

At 12 months, there was an average weight loss of 16.2%, with results sustained up to 24 months

In this limited series, we speak with experts to understand the new frontier of anti-obesity drugs, as well as concerns and questions that still remain.

I could only shake my head when I read Dr. Donna Ryan’s letter regarding U.S. Sen. Bill Cassidys bill that would allow Medicare funds to be used for anti-obesity drugs.